Targeting cryptic splicing variants in SDCCAG8, CEP290, and ABCA4: A translational workflow from diagnosis to ASO-based therapy
Variant / mechanism
SDCCAG8
Deep intronic and silent variants inducing aberrant splicing (pseudoexon inclusion), corrected by splice-switching antisense oligonucleotides
Summary
The authors propose an integrated workflow from variant discovery to RNA-based therapy in inherited retinal diseases. Genome sequencing identified three cryptic variants in known genes: two novel deep intronic SDCCAG8 variants, shown by RT-PCR to induce pseudoexon inclusion, and a previously described deep intronic CEP290 variant whose aberrant splicing was reproduced in patient fibroblasts. A third family carrying the recurrent silent ABCA4 c.768G>T variant was added as an additional model for correction. Sixteen splice-switching antisense oligonucleotides were tested in patient fibroblasts, HeLa cells transfected with mutant minigenes and, when available, iPSC-derived retinal organoids; for each variant, at least one oligonucleotide improved normal splicing and increased gene expression.
Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.
Analysis
The value lies in the full chain: the genome captures deep intronic variants out of reach of the exome, splicing evidence makes them classifiable, and the same evidence becomes the starting point for a tailored oligonucleotide. This remains preclinical, in three families and without in vivo data; but for cryptic splicing variants in inherited retinal diseases, this path from diagnosis to individualised therapy is becoming concrete.
Analysis by Dr Thibaut Benquey
Why this score?
Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 0/1 · Publication status: 1/1 → Total: 6/10
Keywords
Every Wednesday · Annotated selection · Free · Unsubscribe anytime